## **Supplementary Online Content**

Hargreave M, Jensen A, Hansen MK, et al. Association between fertility treatment and cancer risk in children. *JAMA*. doi:10.1001/jama.2019.18037

- **eTable 1.** The Danish Infertility Cohort (DIC), comprising virtually all women in Denmark requiring fertility assistance in the period 1963-2012, based on information obtained from several Danish nationwide population-based registries and local databases
- eTable 2. Baseline characteristics of children conceived after assisted reproduction technology.
- **eTable 3.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for hematological cancers according to maternal infertility and treatment
- **eTable 4.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for neural cancers according to maternal infertility and treatment
- **eTable 5.** Hazard ratios, incidence rates and incidence rate differences for other cancers according to maternal infertility and treatment
- **eTable 6.** Hazard ratios adjusted for sex and perinatal factors for any childhood cancer according to maternal infertility and treatment
- **eTable 7.** Hazard ratios, incidence rates and incidence rate differences for any childhood cancer according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference
- **eTable 8.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for hematological cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference
- **eTable 9.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for neural cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference
- **eTable 10.** Hazard ratios, incidence rates and incidence rate differences for other cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference
- **eTable 11.** Hazard ratios taking into account sibling clustering for any childhood cancer according to maternal infertility and treatment
- **eFigure.** Identification of the study cohort

**eReferences** 

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. The Danish Infertility Cohort (DIC), comprising virtually all women in Denmark requiring fertility assistance in the period 1963-2012, based on information obtained from several Danish nationwide population-based registries and local databases

		Data So	ources	
	Local databases	National Prescription Register <sup>a</sup>	National Patient Registry <sup>b</sup>	IVF Register <sup>c</sup>
Established		1994	1976	1994
Complete from		1995	1977	1994
Data period included in the DIC	1963-1989	1995-2012	1977-2012	1994-2012
Examples of data included	PIN of women referred to public gynecological hospital departments or private fertility clinics for fertility problems identified through local electronic databases	Redeemed prescriptions for fertility drugs	Discharge diagnoses, and dates of diagnoses	Assisted reproduction technology treatments, treatment dates, fertility drugs used
PIN <sup>d</sup> included	Yes	Yes	Yes	Yes
Criteria for women included in the DIC 1963-2012	All women identified	Women who redeemed prescriptions for fertility drugs <sup>e</sup>	Women with a diagnosis of infertility <sup>f</sup>	All women recorded in the registry
<sup>a</sup> Reimbursement-driven, with au <sup>b</sup> Contains information on all con reported in this registry accordin according to International classif for up to 83% of all cases. <sup>2</sup> <sup>c</sup> It is obligatory for all IVF clinics data. <sup>3</sup>	tacts with Danish hospitals si g to the International classific ication of diseases, revision 1	nce 1977 and outpatient conta ation of diseases, revision 8 ( 0 (ICD-10). A comparison of	acts since 1995. Before 1995 ICD-8), whereas, after 1994, various primary diagnoses s	they were reported howed correct categorization

<sup>&</sup>lt;sup>d</sup> PIN = personal identification number given to all Danish residents.
<sup>e</sup> Anatomical Therapeutical Chemical (ATC) codes: G03CA\*, G03DA04, G03GA\*, G03GB02, G03DA02, H01CA\*, H01CC\*, L02AE\*, L02AB02 and N04BC01

<sup>&</sup>lt;sup>f</sup> ICD-8 code 628 and ICD-10 code N97.

eTable 2. Baseline characteristics of children conceived after assisted reproduction technology

			Туре	of assisted rep	oroduction techn	ology			
	In vitro fe	ertilization		smic sperm	Frozen embryo	o replacement	Othe	er/unknown	
	N	(%)	N	(%)	N	(%)	N	(%)	pa
Total	19,448	(100.0)	13,417	(100.0)	3,356	(100.0)	935	(100.0)	
Year of birth									<0.001
1996 -1999	5,622	(28.9)	2,086	(15.5)	539	(16.1)	124	(13.3)	
2000-2003	5,119	(26.3)	3,360	(25.0)	536	(16.0)	79	(8.4)	
2004-2007	4,648	(23.9)	3,856	(28.7)	945	(28.2)	234	(25.0)	
2008-2012	4,059	(20.9)	4,115	(30.7)	1,336	(39.8)	498	(53.3)	
Median [IQR] years	2004 [20	000-2008]	2006 [20	002-2009]	2007 [20	03-2010]	2009	[2006-2010]	
Sex									<0.001
Female	9,275	(47.7)	6,900	(51.4)	1,683	(50.1)	461	(49.3)	
Male	10,173	(52.3)	6,517	(48.6)	1,673	(49.9)	474	(50.7)	
Birth weight (g)									<0.001
< 2500	3,622	(18.6)	2,357	(17.6)	410	(12.2)	191	(20.4)	
2500-4500	14,339	(73.7)	10,589	(78.9)	2,753	(82.0)	700	(74.9)	
> 4500	292	(1.5)	231	(1.7)	109	(3.2)	12	(1.3)	
Missing	1,195	(6.1)	240	(1.8)	84	(2.5)	32	(3.4)	
Median [IQR] g	3,150 [2,6	625-3,600]	3,200 [2,	95-3,640]	3,400 [2,8	70-3,839]	3,160	[2,622-3,615]	
Multiplicity									<0.001
No	12,626	(64.9)	9,001	(67.1)	2,479	(73.9)	635	(67.9)	
Yes	6,822	(35.1)	4,416	(32.9)	877	(26.1)	300	(32.1)	
Gestational age (weeks)									<0.001
< 37	4,248	(21.8)	2,536	(18.9)	524	(15.6)	195	(20.9)	
37-42	14,815	(76.2)	10,615	(79.1)	2,738	(81.6)	715	(76.5)	
> 42	385	(2.0)	266	(2.0)	94	(2.8)	25	(2.7)	
Median [IQR] weeks	38.7 [37	7.1-40.3]	39.0 [3]	7.4-40.4]	39.3 [37	. <u>9-40.7]</u>	38.7	[37.1-40.4]	

 $<sup>\</sup>hbox{@ 2019}$  American Medical Association. All rights reserved.

			Туре	of assisted re	production techn	ology			
	In vitro fe	ertilization		asmic sperm ction	Frozen embryo	replacement	Othe	er/unknown	
	N	(%)	N	(%)	N	(%)	N	(%)	pª
Birth order									<0.001
1	13,639	(70.1)	9,486	(70.7)	1,826	(54.4)	612	(65.5)	
<u>&gt;</u> 2	5,809	(29.9)	3,931	(29.3)	1,530	(45.6)	323	(34.5)	
Maternal smoking <sup>b</sup>									<0.001
No	15,383	(79.1)	11,650	(86.8)	2,905	(86.6)	784	(83.9)	
Yes	2,268	(11.7)	1,199	(8.9)	287	(8.6)	88	(9.4)	
Missing	1,797	(9.2)	568	(4.2)	164	(4.9)	63	(6.7)	
Paternal age at birth (years)									<0.001
<30	1,992	(10.2)	1,518	(11.3)	302	(9.0)	<60	-	
30 -34	7,067	(36.3)	4,845	(36.1)	1,183	(35.3)	219	(23.4)	
>34	10,086	(51.9)	7,022	(52.3)	1,839	(54.8)	653	(69.8)	
Missing	303	(1.6)	32	(0.2)	32	(1.0)	<5	_	
Median [IQR] years	35.3 [32	2.3-38.9]		2.2-39.0]	35.6 [32			[34.1-43.7]	
Maternal age at birth (years)									<0.001
<30	3,454	(17.8)	3,235	(24.1)	564	(16.8)	142	(15.2)	
30 -34	8,433	(43.4)	6,005	(44.8)	1,531	(45.6)	326	(34.9)	
>34	7,561	(38.9)	4,177	(31.1)	1,261	(37.6)	467	(49.9)	
Median [IQR] years	,	0.9-36.7]	· · · · · · · · · · · · · · · · · · ·	0.1-35.8]	33.8 [31			[31.4-38.8]	
Paternal educational level									<0.001
Basic	3,910	(20.1)	2,617	(19.5)	668	(19.9)	197	(21.1)	
Vocational	9,144	(47.0)	6,614	(49.3)	1,505	(44.8)	468	(50.1)	
Higher	5,713	(29.4)	3,929	(29.3)	1,097	(32.7)	252	(27.0)	
Missing	681	(3.5)	257	(1.9)	86	(2.6)	18	(1.9)	

 $<sup>\</sup>hbox{@ 2019}$  American Medical Association. All rights reserved.

			Туре	of assisted re	production techn	ology			
	In vitro fo	ertilization		smic sperm ction	Frozen embryo	o replacement	Othe	er/unknown	
	N	(%)	N	(%)	N	(%)	N	(%)	pa
Maternal educational level									<0.001
Basic	3,943	(20.3)	2,316	(17.3)	589	(17.6)	167	(17.9)	
Vocational	7,572	(38.9)	5,311	(39.6)	1,173	(35.0)	344	(36.8)	
Higher	7,733	(39.8)	5,632	(42.0)	1,544	(46.0)	402	(43.0)	
Missing	200	(1.0)	158	(1.2)	50	(1.5)	22	(2.4)	

<sup>&</sup>lt;sup>a</sup> The p-values reflect a comparison of the three groups for each variable. The Chi2 test was used for the categorical variables and the Kruskal-Wallis test for the continuous variables.

<sup>&</sup>lt;sup>b</sup> Measured during first trimester of pregnancy.

IQR = Interquartile range.

**eTable 3.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for hematological cancers according to maternal infertility and treatment

					Leukar	nias					Lymph	omas		
	Person- years	No. of children	No. of events	HR <sup>a,b</sup>	95% CI	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	95% CI	No. of events	HR <sup>a,b</sup>	95% CI	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	95% CI
Maternal infertility <sup>d</sup>														
No	10,385,749	910,291	538	1	(Ref.)	4.3	0	(Ref.)	211	1	(Ref.)	2.4	0	(Ref.)
Yese	1,824,545	174,881	110	1.11	(0.90-1.37)	4.9	0.6	(-0.6-1.8)	31	0.86	(0.59-1.26)	1.9	-0.5	(-1.1-0.1)
Maternal fertility treatment <sup>f</sup>	943,199	89,981	55	1.08	(0.82-1.43)	4.8	0.5	(-1.0-2.1)	15	0.80	(0.47-1.34)	1.8	-0.6	(-1.4-0.2)
Hormonal treatment	934,946	89,334	54	1.07	(0.81-1.41)	4.8	0.5	(-1.1-2.1)	15	0.80	(0.48-1.36)	1.8	-0.6	(-1.4-0.2)
Clomiphene	372,402	33,835	21	1.06	(0.69-1.64)	4.9	0.6	(-1.9-3.0)	<5	0.40	(0.13-1.26)	-	-	-
Gonadotropins	572,515	57,136	39	1.23	(0.89-1.71)	5.6	1.3	(-0.8-3.5)	7	0.62	(0.29-1.33)	1.5	-0.9	(-1.7-0.0)
Human chorionic gonadotropin	682,288	68,181	41	1.09	(0.79-1.50)	4.8	0.5	(-1.4-2.4)	12	0.89	(0.50-1.59)	1.9	-0.5	(-1.4-0.4)
Gonadotropin- releasing hormone analogues	393,199	38,653	26	1.21	(0.81-1.79)	5.5	1.2	(-1.4-3.8)	7	0.91	(0.43-1.92)	2.0	-0.3	(-1.6-0.9)
Progesterone	429,787	41,628	28	1.20	(0.82-1.76)	5.3	1.0	(-1.4-3.4)	9	1.05	(0.54-2.04)	2.5	0.1	(-1.3-1.4)
Estrogene	123,958	16,948	8	1.00	(0.50-2.03)	3.8	-0.5	(-4.7-3.7)	<5	1.16	(0.37-3.66)	-	-	-
Other/unknown	73,129	8,867	<5	0.89	(0.33-2.39)	-	-	-	<5	1.30	(0.32-5.26)	-	-	-
Assisted reproduction technologies	388,681	37,156	<30	1.28	(0.87-1.88)	5.8	1.5	(-1.1-4.1)	8	1.04	(0.52-2.12)	2.4	0.0	(-1.4-1.4)
In vitro fertilization	220,159	19,448	11	0.95	(0.52-1.73)	4.1	-0.2	(-3.1-2.8)	<5	0.68	(0.22-2.14)	-	-	-
Intracytoplasmic sperm injection	130,726	13,417	10	1.36	(0.73-2.54)	6.6	2.3	(-2.5-7.1)	<5	1.20	(0.38-3.77)	-	-	-
Frozen embryo replacement	30,260	3,356	5	2.87	(1.19-6.93)	14.4	10.1	(-4.0-24.2)	<5	3.24	(0.81-13.10)	-	1	-
Other/unknown	7,536	935	<5	2.19	(0.31-15.59)	-	-	-	0	-	-	-	-	-
<sup>a</sup> Adjusted for year of birth of the	child.				,									
<sup>b</sup> Each HR is generated from a s	eparate analysis	comparing the	he children	with eacl	n individual expos	ure to th	e first row	(i.e. children bor	rn to fertile wo	men).				
° Per 100,000 person-years.														
d Anytime before birth of the child	d.													
e Children born to women requiri		ance on inde	x or prior pr	egnancv	<u> </u>									
	J		2. pa. pi	- 9						İ		1		<u>i</u>

<sup>© 2019</sup> American Medical Association. All rights reserved.

<sup>f</sup> In index pregnancy.						
CI = confidence interval.						

eTable 4. Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for neural cancers according to maternal infertility and treatment

				Centra	l nervous sys	tem n	eoplasm	s		Sympa	thetic nervou	ıs syst	em tumo	ors
	Person- years	No. of children	No. of events	HR <sup>a,b</sup>	95% CI	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	95% CI	No. of events	HR <sup>a,b</sup>	95% CI	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	95% CI
Maternal infertility <sup>d</sup>														
No	10,385,749	910,291	459	1	(Ref.)	4.3	0	(Ref.)	113	1	(Ref.)	0.9	0	(Ref.)
Yes <sup>e</sup>	1,824,545	174,881	82	1.01	(0.80-1.28)	4.3	0.0	(-1.0- 1.1)	17	0.81	(0.49-1.35)	0.7	-0.2	(-0.6-0.3)
Maternal fertility treatment <sup>f</sup>	943,199	89,981	48	1.15	(0.85-1.54)	4.9	0.6	(-0.8- 2.1)	9	0.83	(0.42-1.64)	0.7	-0.1	(-0.8-0.5)
Hormonal treatment	934,946	89,334	47	1.13	(0.84-1.53)	4.9	0.6	(-0.9- 2.1)	8	0.74	(0.36-1.53)	0.6	-0.2	(-0.8-0.3)
Clomiphene	372,402	33,835	21	1.27	(0.82-1.97)	5.5	1.2	(-1.2- 3.7)	<5	0.73	(0.23-2.29)	-	-	=
Gonadotropins	572,515	57,136	31	1.22	(0.85-1.75)	5.2	1.0	(-1.0- 2.9)	<5	0.59	(0.22-1.60)	-	-	=
Human chorionic gonadotropin	682,288	68,181	33	1.09	(0.76-1.55)	4.7	0.4	(-1.3- 2.1)	8	0.99	(0.48-2.03)	0.9	0.0	(-0.8-0.8)
Gonadotropin- releasing hormone analogues	393,199	38,653	20	1.14	(0.73-1.79)	5.0	0.7	(-1.6- 2.9)	<5	0.43	(0.11-1.76)	-	-	-
Progesterone	429,787	41,628	18	0.94	(0.59-1.51)	4.0	-0.3	(-2.2- 1.7)	<5	0.40	(0.10-1.62)	-	-	-
Estrogen	123,958	16,948	5	0.88	(0.36-2.14)	-	-	-	<5	0.55	(0.08-3.98)	-	-	-
Other/unknown	73,129	8,867	5	1.52	(0.63-3.68)	6.7	2.4	(-3.7- 8.4)	0	-	-	-	-	-
Assisted reproduction technologies	388,681	37,156	<25	1.22	(0.79-1.89)	5.3	1.0	(-1.4- 3.3)	<5	0.89	(0.33-2.42)	-	-	-
In vitro fertilization	220,159	19,448	9	0.93	(0.48-1.79)	4.0	-0.3	(-3.0- 2.4)	<5	0.42	(0.06-2.97)	-	-	=
Intracytoplasmic sperm injection	130,726	13,417	10	1.72	(0.92-3.22)	7.5	3.2	(-1.6- 8.0)	0	-	-	-	-	-
Frozen embryo replacement	30,260	3,356	<5	1.47	(0.37-5.91)	-	-	-	<5	7.82	(2.47- 24.70)	-	-	-
Other/unknown	7,536	935	0	-	-	-	-	-	0	-	-	-	-	-

<sup>© 2019</sup> American Medical Association. All rights reserved.

<sup>a</sup> Adjusted for year of birth of the child.											
<sup>b</sup> Each HR is generated from a separate an	alysis comparing the	children with	n each inc	lividual exposure	to the fire	st row (i.e.	children born t	o fe	rtile women)		
° Per 100,000 person-years.											
d Anytime before birth of the child.											
<sup>e</sup> Children born to women requiring fertility a	assistance on index o	r prior pregn	nancy.	•	ı						
fin index pregnancy. Includes only the item	s listed below.										
"-" indicates that it was not possible to esting	mate the number in tl	ne model. CI	= confide	ence interval.							

eTable 5. Hazard ratios, incidence rates and incidence rate differences for other cancers according to maternal infertility and treatment

	Person- years	Number of children	Number of events	Hazard ratio <sup>a,b</sup>	95% confidence interval	Incidence rate <sup>a</sup> per 100,000 person- years	Incidence rate difference <sup>a</sup> per 100,000 person-years	95% confidence interval
Maternal infertility <sup>c</sup>								
No	10,385,749	910,291	559	1	(Reference)	5.7	0	(Reference)
Yesd	1,824,545	174,881	102	1.05	(0.85-1.30)	5.8	0.1	(-1.1-1.2)
Maternal fertility treatmente	943,199	89,981	52	1.03	(0.77-1.37)	5.7	0.0	(-1.6-1.5)
Hormonal treatment	934,946	89,334	50	1.00	(0.75-1.33)	5.3	-0.2	(-1.7-1.3)
Clomiphene	372,402	33,835	17	0.86	(0.53-1.39)	4.7	-1.0	(-3.1-1.1)
Gonadotropins	572,515	57,136	32	1.05	(0.74-1.51)	5.9	0.2	(-1.8-2.1)
Human chorionic gonadotropin	682,288	68,181	35	0.96	(0.68-1.35)	5.6	-0.1	(-1.9-1.6)
Gonadotropin-releasing hormone analogues	393,199	38,653	26	1.24	(0.84-1.84)	7.0	1.3	(-1.3-3.9)
Progesterone	429,787	41,628	28	1.21	(0.83-1.77)	6.7	1.0	(-1.4-3.4)
Estrogen	123,958	16,948	6	0.84	(0.37-1.88)	4.8	-0.8	(-4.7-3.0)
Other/unknown	73,129	8,867	<5	0.97	(0.36-2.61)	-	-	-
Assisted reproduction technologies	388,681	37,156	<30	1.22	(0.81-1.82)	6.8	1.2	(-1.4-3.7)
In vitro fertilization	220,159	19,448	14	1.20	(0.71-2.04)	6.8	1.1	(-2.3-4.4)
Intracytoplasmic sperm injection	130,726	13,417	9	1.32	(0.68-2.55)	7.3	1.6	(-2.9-6.1)
Frozen embryo replacement	30,260	3,356	<5	1.20	(0.30-4.81)	-	-	-
Other/unknown	7,536	935	0	-	=	-	-	-
<sup>a</sup> Adjusted for year of birth of the child.								
b Each hazard ratio is generated from a separ women). c Anytime before birth of the child.	ate analysis comp	paring the child	dren with each	individual exp	oosure to the first ro	ow (i.e. children b	orn to fertile	
•	<u> </u>							
d Children born to women requiring fertility as:		or prior pregna	ancy.					
$^{\rm e}\mbox{In}$ index pregnancy. Includes only the items	listed below.							

 $<sup>\</sup>hbox{@ 2019}$  American Medical Association. All rights reserved.

eTable 6. Hazard ratios adjusted for sex and perinatal factors for any childhood cancer according to maternal infertility and treatment

	Person- years	Number of children	Number of events	Complete case hazard ratio <sup>a,b</sup>	(95% confidence interval)	Adjusted hazard ratio <sup>a,b,c</sup>	(95% confidence interval)
Maternal infertility <sup>d</sup>				1000			
No	9,222,935	846,489	16663	1	(Reference)	1	(Reference)
Yese	1,696,691	167,742	319	1.03	(0.91-1.16)	1.03	(0.91-1.17)
Maternal fertility treatment <sup>f</sup>	862,363	85,486	164	1.04	(0.88-1.22)	1.05	(0.89-1.24)
Hormonal treatment	854,794	84,876	159	1.01	(0.86-1.19)	1.02	(0.86-1.21)
Clomiphene	337,329	31,929	57	0.93	(0.72-1.22)	0.94	(0.74-1.22)
Gonadotropins	536,531	55,071	105	1.06	(0.87-1.30)	1.08	(0.88-1.33)
Human chorionic gonadotropin	634,231	65,469	120	1.02	(0.85-1.23)	1.04	(0.85-1.26)
Gonadotropin-releasing hormone analogues	366,370	37,122	75	1.11	(0.88-1.41)	1.14	(0.89-1.45)
Progesterone	394,545	39,632	80	1.10	(0.88-1.38)	1.12	(0.89-1.42)
Estrogen	121,951	16,783	23	0.93	(0.61-1.40)	0.94	(0.62-1.43)
Other/unknown	69,016	8,629	15	1.10	(0.66-1.83)	1.11	(0.67-1.86)
Assisted reproduction technology	361,025	35,605	<90	1.21	(0.97-1.52)	1.25	(0.99-1.58)
In vitro fertilization	198,532	18,253	34	0.95	(0.68-1.34)	0.96	(0.68-1.36)
Intracytoplasmic sperm injection	126,742	13,177	31	1.33	(0.93-1.90)	1.36	(0.95-1.96)
Frozen embryo replacement	28,769	3,272	14	2.55	(1.51-4.32)	2.58	(1.52-4.38)
Other/unknown	6,981	903	<5	0.71	(0.10-5.05)	0.72	(0.10-5.10)
<sup>a</sup> Adjusted for year of birth of the child.							
<sup>b</sup> Each hazard ratio is generated from a separate	analysis compari	ng the children with	each individual expos	sure to the first row (i.e.	children born to fertil	e women).	
° Adjusted for sex and perinatal factors (birthweig	ht [<2500, 2500-4	4500, >4500g], gest	ational length [<37, 37	'-43, >43 weeks] and n	nultiplicity [yes, no]) .		
<sup>d</sup> Anytime before birth of the child.							
<sup>e</sup> Children born to women requiring fertility assista	ance on index or	prior pregnancy.					
<sup>f</sup> In index pregnancy. Includes only the items liste	d below.						

**eTable 7.** Hazard ratios, incidence rates and incidence rate differences for any childhood cancer according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference

	Person- years	Number of children	Number of events	Hazard ratio <sup>a,b</sup>	(95% confidence interval)	Incidence rate <sup>a</sup> per 100,000 person- years	Incidence rate difference <sup>a</sup> per 100,000 person- years	(95% confidence interval)
Maternal fertility treatment <sup>c</sup>							youro	
No	881,346	84,900	163	1	(Reference)	17.4	0	(Reference)
Yes	943,199	89,981	178	1.02	(0.82-1.26)	17.8	0.4	(-3.5-4.4)
Hormonal treatment	934,946	89,334	173	0.99	(0.80-1.23)	17.4	0.0	(-3.9-3.9)
Clomiphene	372,402	33,835	64	0.93	(0.70-1.25)	16.7	-0.7	(-5.8-4.4)
Gonadotropins	572,515	57,136	112	1.05	(0.82-1.33)	18.6	1.2	(-3.4-5.7)
Human chorionic gonadotropin	682,288	68,181	129	1.01	(0.80-1.27)	17.7	0.3	(-3.9-4.6)
Gonadotropin-releasing hormone analogues	393,199	38,653	81	1.11	(0.85-1.44)	19.7	2.3	(-2.9-7.6)
Progesterone	429,787	41,628	85	1.06	(0.82-1.38)	18.6	1.2	(-3.8-6.2)
Estrogen	123,958	16,948	23	0.90	(0.58-1.40)	16.1	-1.3	(-9.4-6.7)
Other/unknown	73,129	8,867	15	1.03	(0.61-1.75)	17.2	-0.2	(-10.5-10.2)
Assisted reproduction technologies	388,681	37,156	<90	1.18	(0.91-1.53)	21.0	3.6	(-1.8-9.0)
In vitro fertilization	220,159	19,448	38	0.95	(0.66-1.35)	17.1	-0.3	(-6.5-5.9)
Intracytoplasmic sperm injection	130,726	13,417	32	1.31	(0.90-1.92)	23.1	5.7	(-3.1-14.5)
Frozen embryo replacement	30,260	3,356	14	2.39	(1.39-4.13)	44.4	27.0	(2.7-51.3)
Other/unknown	7,536	935	<5	0.65	(0.09-4.66)	-	-	-
<sup>a</sup> Adjusted for year of birth of the child.								
<sup>b</sup> Each hazard ratio is generated from a se assistance without treatment in index preg <sup>c</sup> Children born to women requiring fertility	gnancy).  v assistance on i	ndex or prior pregr		·		children born to	women requiring t	ertility
"-" indicates that it was not possible to es	timate the numb	er in the model.						

<sup>© 2019</sup> American Medical Association. All rights reserved.

**eTable 8.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for hematological cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference

					Leuker	nias					Lympho	mas		
	Person- years	No. of children	No. of events	HR <sup>a,b</sup>	(95% CI)	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	(95% CI)	No. of events	HR <sup>a,b</sup>	(95% CI)	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	(95% CI)
Maternal fertility treatment <sup>d</sup>														
No	881,346	84,900	55	1	(Ref.)	5.0	0	(Ref.)	16	1	(Ref.)	2.2	0	(Ref.)
Yes	943,199	89,981	55	0.94	(0.65-1.37)	4.8	-0.1	(-2.4-2.1)	15	0.86	(0.42-1.73)	1.8	-0.2	(-1.2-0.9)
Hormonal treatment	934,946	89,334	54	0.93	(0.64-1.36)	4.8	-0.2	(-2.4-2.0)	15	0.806	(0.43-1.75)	1.8	-0.2	(-1.2-0.9)
Clomiphene	372,402	33,835	21	0.93	(0.56-1.53)	4.9	-0.1	(-3.0-2.8)	<5	0.43	(0.13-1.49)	-	-	-
Gonadotropins	572,515	57,136	39	1.07	(0.71-1.62)	5.6	0.6	(-2.0-3.3)	7	0.67	(0.28-1.63)	1.5	-0.4	(-1.6-0.7)
Human chorionic gonadotropin	682,288	68,181	41	0.95	(0.63-1.42)	4.8	-0.2	(-2.6-2.3)	12	0.96	(0.45-2.02)	1.9	-0.1	(-1.3-1.1)
Gonadotropin- releasing hormone analogues	393,199	38,653	26	1.05	(0.66-1.68)	5.5	0.5	(-2.5-3.5)	7	0.97	(0.40-2.37)	2.0	-0.2	(-1.2-0.9)
Progesterone	429,787	41,628	28	1.05	(0.67-1.65)	5.3	0.3	(-2.5-3.2)	9	1.13	(0.50-2.55)	2.5	0.5	(-1.1-2.1)
Estrogen	123,958	16,948	8	0.88	(0.42-1.85)	3.8	-1.2	(-5.6-3.3)	<5	1.25	(0.36-4.31)	-	-	-
Other/unknown	73,129	8,867	<5	0.78	(0.28-2.15)	-	-	-	<5	1.40	(0.32-6.10)	-	-	-
Assisted reproduction technologies.	388,681	37,156	<30	1.12	(0.70-1.77)	5.8	8.0	(-2.2-3.8)	8	1.12	(0.48-2.62)	2.4	0.4	(-1.2-2.0)
In vitro fertilization	220,159	19,448	11	0.83	(0.44-1.59)	4.1	-0.9	(-4.2-2.5)	<5	0.74	(0.21-2.53)	-	-	-
Intracytoplasmic sperm injection	130,726	13,417	10	1.18	(0.60-2.32)	6.6	1.6	(-3.4-6.7)	<5	1.29	(0.38-4.44)	-	-	-
Frozen embryo replacement	30,260	3,356	5	2.50	(1.10-6.26)	14.4	9.4	(-4.8-23.6)	<5	3.49	(0.80-15.21)	-	-	-
Other/unknown	7,536	935	<5	1.91	(0.26- 13.81)	-	-	-	0	-	-	-	-	-

<sup>&</sup>lt;sup>b</sup> Each hazard ratio is generated from a separate analysis comparing the children with each individual exposure to the first row (i.e. children born to women requiring fertility assistance without treatment in index pregnancy).

<sup>°</sup>Per 100,000 person-years

<sup>&</sup>lt;sup>d</sup> Children born to women requiring fertility assistance on index or prior pregnancy. Includes only the items listed below.

<sup>&</sup>quot;-" indicates that it was not possible to estimate the number in the model. CI= confidence interval.

**eTable 9.** Hazard ratios (HRs), incidence rates (IRs) and incidence rate differences (IRDs) for neural cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference

99 46	No. of children 84,900 89,981	No. of events	HR <sup>a,b</sup>	(95% CI)	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	(95% CI)	No. of events	HR <sup>a,b</sup>	(95% CI)	IR <sup>a,c</sup>	IRD <sup>a,c</sup>	(95% CI)
99	,		1					CVCIILO					
99	,		1										
	89,981	40	1	(Ref.)	3.6	0	(Ref.)	8	1	(Ref.)	0.7	0	(Ref.)
46		48	1.32	(0.85- 2.04)	4.9	1.4	(-0.6-3.3)	9	1.06	(0.41-2.74)	0.7	0.0	(-0.8- 0.9)
	89,334	47	1.30	(0.84- 2.02)	4.9	1.3	(-0.6-3.2)	8	0.95	(0.35-2.52)	0.6	-0.1	(-0.9- 0.8)
02	33,835	21	1.46	(0.85- 2.52)	5.5	2.0	(-0.8-4.7)	<5	0.93	(0.25-3.49)	-	-	-
15	57,136	31	1.40	(0.86- 2.28)	5.2	1.6	(-0.6-3.9)	<5	0.75	(0.23-2.50)	-	-	-
88	68,181	33	1.25	(0.77- 2.01)	4.7	1.1	(-1.0-3.2)	8	1.26	(0.47-3.35)	0.9	0.2	(-0.8- 1.2)
99	38,653	20	1.32	(0.76- 2.28)	4.9	1.4	(-1.2-3.9)	<5	0.55	(0.12-2.60)	-	-	-
87	41,628	18	1.08	(0.61- 1.92)	4.0	0.4	(-1.9-2.7)	<5	0.51	(0.11-2.39)	-	-	-
58	16,948	5	1.01	(0.39- 2.60)	-	-	-	<5	0.70	(0.09-5.63)	-	-	-
29	8,867	5	1.74	(0.68- 4.47)	6.6	3.1	(-3.1-9.2)	0	-	-	-	-	-
81	37,156	<25	1.40	(0.81- 2.41)	5.2	1.7	(-1.0-4.3)	<5	1.14	(0.34-3.77)	-	-	-
59	19,448	9	1.06	(0.51- 2.22)	4.0	0.4	(-2.6-3.4)	<5	0.53	(0.07-4.22)	-	-	-
26	13,417	10	1.98	(0.98- 4.00)	7.4	3.9	(-1.0-8.8)	0	-	-	-	-	-
60	3,356	<5	1.69	(0.41- 7.03)	-	-	-	<5	9.94	(2.63- 37.54)	-	-	-
6	935	0	-	-	-	-	-	0	-	-	-	-	-
7 7 7 3	402 515 288 199 787 958 29 681 159 726 60 36	515 57,136 288 68,181 199 38,653 787 41,628 958 16,948 29 8,867 681 37,156 159 19,448 726 13,417 160 3,356 36 935	515 57,136 31 288 68,181 33 199 38,653 20 787 41,628 18 958 16,948 5 29 8,867 5 681 37,156 <25 159 19,448 9 726 13,417 10 160 3,356 <5 36 935 0	515     57,136     31     1.40       288     68,181     33     1.25       199     38,653     20     1.32       787     41,628     18     1.08       958     16,948     5     1.01       29     8,867     5     1.74       681     37,156     <25	402         33,835         21         1.46         (0.85-2.52)           515         57,136         31         1.40         (0.86-2.28)           288         68,181         33         1.25         (0.77-2.01)           199         38,653         20         1.32         (0.76-2.28)           787         41,628         18         1.08         (0.61-1.92)           958         16,948         5         1.01         (0.39-2.60)           29         8,867         5         1.74         (0.68-4.47)           681         37,156         <25	402         33,835         21         1.46         (0.85-2.52)         5.5           515         57,136         31         1.40         (0.86-2.28)         5.2           288         68,181         33         1.25         (0.77-2.01)         4.7           199         38,653         20         1.32         (0.76-2.28)         4.9           787         41,628         18         1.08         (0.61-1.92)         4.0           958         16,948         5         1.01         (0.39-2.60)         -           29         8,867         5         1.74         (0.68-4.47)         6.6           681         37,156         <25	402     33,835     21     1.46     (0.85-2.52)     5.5     2.0       515     57,136     31     1.40     (0.86-2.28)     5.2     1.6       288     68,181     33     1.25     (0.77-2.01)     4.7     1.1       199     38,653     20     1.32     (0.76-2.28)     4.9     1.4       787     41,628     18     1.08     (0.61-4.0)     0.4       958     16,948     5     1.01     (0.39-2.60)     -     -       29     8,867     5     1.74     (0.68-4.7)     6.6     3.1       681     37,156     <25	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)           515         57,136         31         1.40         (0.86-2.28)         5.2         1.6         (-0.6-3.9)           288         68,181         33         1.25         (0.77-2.01)         4.7         1.1         (-1.0-3.2)           199         38,653         20         1.32         (0.76-2.28)         4.9         1.4         (-1.2-3.9)           787         41,628         18         1.08         (0.61-4.0)         4.0         0.4         (-1.9-2.7)           958         16,948         5         1.01         (0.39-2.60)         -         -         -           29         8,867         5         1.74         (0.68-4.47)         6.6         3.1         (-3.1-9.2)           3681         37,156         <25	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)         <5	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)         <5	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)         <5	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)         <5	402         33,835         21         1.46         (0.85-2.52)         5.5         2.0         (-0.8-4.7)         <5

b Each hazard ratio is generated from a separate analysis comparing the children with each individual exposure to the first row (i.e. children born to women requiring fertility assistance without treatment in index pregnancy).

<sup>&</sup>lt;sup>c</sup> Per 100,000 person-years

hildren born to women requiring fertility assistance on index or prior pregnancy. Includes only the items listed below.	
indicates that it was not possible to estimate the number in the model. CI= confidence interval.	

**eTable 10.** Hazard ratios, incidence rates and incidence rate differences for other cancers according to maternal fertility treatment, using children born to women requiring fertility assistance (without treatment in index pregnancy) as reference

	Person- years	Number of children	Number of events	Hazard ratio <sup>a,b</sup>	(95% confidence interval)	Incidence rate <sup>a</sup> per 100,000 person- years	Incidence rate difference <sup>a</sup> per 100,000 person- years	(95% confidence interval)
Maternal fertility treatment <sup>c</sup>								
No	881,347	84,900	50	1	(Reference)	5.9	0	(Reference)
Yes	943,201	89,981	52	0.96	(0.90-1.37)	5.7	-0.3	(-2.4-1.8)
Hormonal treatment	934,946	89,334	50	0.93	(0.63-1.37)	5.5	-0.4	(-2.5-1.7)
Clomiphene	372,402	33,835	17	0.80	(0.46-1.38)	4.7	-1.2	(-3.8-1.4)
Gonadotropins	572,515	57,136	32	0.98	(0.63-1.53)	5.9	0.0	(-2.5-2.4)
Human chorionic gonadotropin	682,288	68,181	35	0.89	(0.58-1.37)	5.6	-0.3	(-2.6-1.9)
Gonadotropin-releasing hormone analogues	393,199	38,653	26	1.16	(0.72-1.86)	7.0	1.1	(-1.9-4.0)
Progesterone	429,787	41,628	28	1.13	(0.71-1.79)	6.7	-0.2	(-2.8-2.4)
Estrogen	123,958	16,948	6	0.78	(0.33-1.82)	4.8	-1.1	(-5.2-3.1)
Other/unknown	73,129	8,867	<5	0.90	(0.33-2.50)	-	-	-
Assisted reproduction technologies	388,681	37,156	<30	1.13	(0.70-1.82)	6.9	0.9	(-2.0-3.9)
In vitro fertilization	220,159	19,448	14	1.12	(0.62-2.02)	6.8	0.8	(-2.8-4.5)
Intracytoplasmic sperm injection	130,726	13,417	9	1.23	(0.60-2.49)	7.3	1.4	(-3.3-6.1)
Frozen embryo replacement	30,260	3,356	<5	1.11	(0.27-4.58)	-	-	-
Other/unknown	7,536	935	0	-	-	-	-	-

<sup>&</sup>lt;sup>a</sup> Adjusted for year of birth of the child.


<sup>&</sup>lt;sup>b</sup> Each hazard ratio is generated from a separate analysis comparing the children with each individual exposure to the first row (i.e. children born to women requiring fertility assistance without treatment in index pregnancy).

<sup>°</sup>Children born to women requiring fertility assistance on index or prior pregnancy. Includes only the items listed below.

<sup>&</sup>quot;-" indicates that it was not possible to estimate the number in the model.

eTable 11. Hazard ratios taking into account sibling clustering for any childhood cancer according to maternal infertility and treatment

	Person- years	Number of children	Number of events	hazard ratio <sup>a,b</sup>	(95% confidence interval)		
	years	omarch	CVCITG	Tutio			
Maternal infertility <sup>c</sup>							
No	10,385,749	910,291	1876	1	(Reference)		
Yes <sup>d</sup>	1,824,545	174,881	341	1.02	(0.91-1.15)		
Maternal fertility treatmente	943,199	89,981	178	1.03	(0.88-1.20)		
Hormonal treatment	934,946	89,334	173	1.01	(0.86-1.18)		
Assisted reproduction technology	388,681	37,156	<90	1.20	(0.96-1.49)		
In vitro fertilization	220,159	19,448	38	0.96	(0.70-1.32)		
Intracytoplasmic sperm injection	130,726	13,417	32	1.33	(0.94-1.89)		
Frozen embryo replacement	30,260	3,356	14	2.43	(1.44-4.11)		
Other/unknown	7,536	935	<5	0.66	(0.09-4.71)		
<sup>a</sup> Adjusted for year of birth of the child and taking interest.	account the effe	ct of sibling cluster	ing using robust standar	d errors to account fo	or correlation between siblings.		
<sup>b</sup> Each hazard ratio is generated from a separate an	alysis comparing t	the children with ea	ach inividual exposure to	the first row (i.e. child	dren born to fertile women).		
<sup>c</sup> Anytime before birth of the child.							
<sup>d</sup> Children born to women requiring fertility assistance	e on index or prio	r pregnancy.					
<sup>e</sup> In index pregnancy. Includes only the items listed by	pelow.						



## **eReferences**

- 1 Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. *Scand J Public Health.* 2011; 39(7 Suppl): 38–41.
- Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sorensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clin Epidemiol.*. 2015; 7: 449–490.
- Andersen AN, Westergaard HB, Olsen J. The Danish in vitro fertilisation (IVF) register. *Dan Med Bull.* 1999; 46(4): 357–360.